ETOPOPHOS® 100 mg clinical trials

An open-label, prospective Phase III clinical study to compare polatuzumab vedotin plus rituximab, ifosfamide, carboplatin and etoposide (Pola-R-ICE) with rituximab, ifosfamide, carboplatin and etoposide (R-ICE) alone as salvage therapy in patients with primary refractory or relapsed diffuse large B-cell lymphoma (DLBCL)

This study is for adults with a type of lymphoma called DLBCL that has come back or not responded to earlier treatment. It compares two treatments: a standard one (R-ICE) and a new one (Pola-R-ICE) to see which is better at stopping the cancer from growing.